Agilon Health price target raised to $95 from $13 at Benchmark

Benchmark analyst Bill Sutherland raised the firm’s price target on Agilon Health (AGL) to $95 from $13 and keeps a Buy rating on the shares. Following “remarkable” year-to-date performance, the firm thinks the current valuation “may restrain additional near-term performance,” but adds that it thinks the company is in “the very early days of dramatic margin expansion with the potential for accelerating growth and longer-term stock performance.”